source
- BioNTech spends $205 million on FDA priority review voucher to accelerate oncology pipelineBioNTech has agreed to pay $205 million to acquire an FDA priority review voucher, a tool that can shorten the agency's standard review period from ten months to six months. The voucher was previo…
- Study proposes new obesity metric that could reverse diagnoses for millions, aiming for more precise careResearchers published a study in Nature that suggests an alternative way to define obesity could change the diagnosis status for millions of people. The proposed framework separates pre-clinical an…